Jane Alder
YOU?
Author Swipe
View article: MODELLING IMMUNE CELL INTERACTIONS WITH AN IN VITRO BLOOD BRAIN BARRIER-GLIOMA MODEL
MODELLING IMMUNE CELL INTERACTIONS WITH AN IN VITRO BLOOD BRAIN BARRIER-GLIOMA MODEL Open
AIMS The presence of the blood brain barrier (BBB) may reduce disposition of novel therapies to the brain. Cell-cell interactions in the glioma microenvironment also influence tumour progression. There is a need for an in vitro BBB-glioma m…
View article: Overcoming biological barriers BBB/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy
Overcoming biological barriers BBB/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy Open
A major obstacle for chemotherapeutics in Glioblastoma (GB) is to reach the tumour cells due to the presence of the blood-brain barrier (BBB) and chemoresistance of anticancer drugs. The present study reports two polyunsaturated fatty acid…
View article: Effects of Glycogen Synthase Kinase-3β (GSK3β) Inhibition in Glioblastoma Using Novel Compounds
Effects of Glycogen Synthase Kinase-3β (GSK3β) Inhibition in Glioblastoma Using Novel Compounds Open
AIMS GSK3β is a constitutively conserved serine/threonine kinase involved in a number of biological processes including cell cycle progression, apoptosis, cellular metabolism, proliferation and differentiation. High expression levels in th…
View article: Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3β
Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3β Open
For the first time, the in silico design, screening, and in vitro validation of potent GSK-3β type-II inhibitors are presented. In the absence of crystallographic evidence for a DFG-out GSK-3β activation loop conformation, computational mo…
View article: The identification and validation of novel aptamers for the diagnosis of oligodendroglioma
The identification and validation of novel aptamers for the diagnosis of oligodendroglioma Open
Oligodendroglioma account for nearly 12% of brain tumours (Jain et al., 2017). In the United Kingdom, 0.4 people per 100 000 per year are newly diagnosed with oligodendroglioma (Crocetti et al., 2012). Early diagnosis and treatment of olig…
View article: Folate: Friend or Foe? An investigation into the opposing roles of folate in glioma
Folate: Friend or Foe? An investigation into the opposing roles of folate in glioma Open
Survival rates in patients with glioblastoma have shown little improvement over the last 40 years due to the heterogeneity of tumours and the difficulty of specifically targeting the tumour whilst sparing surrounding healthy tissue. Altere…
View article: DDIS-06. Ku 70/80 IN GLIOMA - TARGETING WITH APTAMERS
DDIS-06. Ku 70/80 IN GLIOMA - TARGETING WITH APTAMERS Open
Aptamers are in vitro generated DNA and RNA sequences. These are randomly present in a library with common primers. Aptamer sequences have multiple permutations and combinations of nucleotides and are then ‘selected’, using Sequential Enum…
View article: Selective Targeting to Glioma with Nucleic Acid Aptamers
Selective Targeting to Glioma with Nucleic Acid Aptamers Open
Malignant glioma is characterised by a rapid growth rate and high capacity for invasive infiltration to surrounding brain tissue; hence, diagnosis and treatment is difficult and patient survival is poor. Aptamers contribute a promising and…